Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project

Since its introduction in 1988, recombinant human erythropoietin (epoetin) has been standard treatment for patients with anemia due to chronic kidney disease. From 1998 to 2004, nearly 200 epoetin-treated persons with chronic kidney disease developed antibodies to epoetin, resulting in pure red cell...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Bennett, Charles L., Cournoyer, Denis, Carson, Kenneth R., Rossert, Jerome, Luminari, Stefano, Evens, Andrew M., Locatelli, Francesco, Belknap, Steven M., McKoy, June M., Lyons, E. Alison, Kim, Benjamin, Sharma, Rishi, Costello, Stacey, Toffelmire, Edwin B., Wells, George A., Messner, Hans A., Yarnold, Paul R., Trifilio, Steven M., Raisch, Dennis W., Kuzel, Timothy M., Nissenson, Allen, Lim, Lay-Cheng, Tallman, Martin S., Casadevall, Nicole
Médium: Artigo
Jazyk:Inglês
Vydáno: The American Society of Hematology 2005
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1895064/
https://ncbi.nlm.nih.gov/pubmed/16099877
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2005-02-0508
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky